Aeglea BioTherapeutics
Biotechnology ResearchView the employees at
Aeglea BioTherapeutics-
Kevin Sunley Bioprocess Development Expert at Aeglea BioTherapeutics with MAb and PEGylation expertise
-
Austin, Texas, United States
-
Rising Star
Justin Crute, CPA Senior Accounting Manager at Aeglea BioTherapeutics-
Rising Star
Sabrina Mendoza Laboratory Technician at Aeglea BioTherapeutics-
Buda, Texas, United States
-
Rising Star
Gail Lawrence Contract CRA at Aeglea BioTherapeutics-
Rising Star
Scott Burrows Chief Financial Officer at Aeglea BioTherapeutics, Inc. (Nasdaq: AGLE)-
Top 10%
Overview
With its acquisition of Spyre Therapeutics, Aeglea is shifting its disease focus to inflammatory bowel disease (IBD). Spyre combines best-in-class antibody engineering, rational therapeutic combinations, and precision immunology approaches to maximize efficacy, safety, and convenience of treatments for IBD. For more information, please visit http://aeglea.com.
-